Trial Profile

Phase I bioequivalence study of single-dose controlled-release pregabalin 165mg versus pregabalin 75mg twice daily under fed conditions

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Nov 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pregabalin (Primary)
Indications Diabetic neuropathies; Fibromyalgia; Neuropathic pain
Focus Pharmacokinetics

Most Recent Events

17 Nov 2014 New trial record
22 Oct 2014 Results published in Intellipharmaceutics International media release.
22 Oct 2014 Primary endpoint (bioequivalence under fed conditions) was met, according to an Intellipharmaceutics International media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com